KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $227000.0.

  • Acadia Pharmaceuticals' Depreciation and Depletion rose 44.25% to $227000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $895000.0, marking a year-over-year decrease of 1112.21%. This contributed to the annual value of $920000.0 for FY2024, which is 3866.67% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Depreciation and Depletion of $227000.0 as of Q3 2025, which was up 44.25% from $213000.0 recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Depreciation and Depletion ranged from a high of $616000.0 in Q3 2021 and a low of $213000.0 during Q2 2025
  • Its 5-year average for Depreciation and Depletion is $386894.7, with a median of $402000.0 in 2023.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Depreciation and Depletion soared by 8224.85% in 2021 and then plummeted by 4378.11% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $535000.0 in 2021, then dropped by 8.6% to $489000.0 in 2022, then crashed by 35.99% to $313000.0 in 2023, then fell by 27.8% to $226000.0 in 2024, then rose by 0.44% to $227000.0 in 2025.
  • Its Depreciation and Depletion was $227000.0 in Q3 2025, compared to $213000.0 in Q2 2025 and $229000.0 in Q1 2025.